SIG reported FY26 revenue of AUD 10.835 billion, compared with pro-forma FY25 revenue of AUD 9.380 billion. Normalised EBIT increased from AUD 903.4 million to AUD 1,090.0 million, representing 20.6% ...
Third Quarter 2026 Financial Results As of September 30, 2026, Nuvation Bio had cash, cash equivalents, and marketable securities of $663.4 million, which includes an additional $36.5 million in net ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results